adenosine has been researched along with Lymphoma, Large B-Cell, Diffuse in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| He, Z; Hong, H; Li, M; Peng, Z; Xie, Z; Xu, Q | 1 |
| Casey, M; Dougall, WC; Gandhi, MK; Law, SC; Lee, C; Madore, J; Nakamura, K; Nowlan, B; Pearson, S; Sabdia, MB; Salik, B; Segawa, K; Winterford, C | 1 |
| Akpa, CA; Dimitrova, L; Hummel, M; Kleo, K; Lenze, D; Oker, E | 1 |
| Bernasconi, E; Bertoni, F; Cascione, L; Dirnhofer, S; Gaudio, E; Gerlach, MM; Mascia, M; Priebe, V; Spriano, F; Stathis, A; Tarantelli, C; Targa, A; Zucca, E | 1 |
| Carson, DA; Daddona, PE; Kamatani, N; Kubota, M | 1 |
| Carson, DA; Iizasa, T; Kubota, M | 1 |
| Berger, M; Cowen, DS; Dubyak, GR; Nuttle, L | 1 |
7 other study(ies) available for adenosine and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Expression of N
Topics: Adenosine; Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Prognosis; Tumor Microenvironment | 2021 |
Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma.
Topics: Adenosine; Humans; Lymphoma, Large B-Cell, Diffuse; Macrophages; Phagocytosis; Rituximab | 2023 |
DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Topics: Adenosine; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Humans; Lymphoma, Large B-Cell, Diffuse; Mutation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-myc; Translocation, Genetic | 2019 |
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice, SCID; Protein Kinase Inhibitors; Pyrazines; Quinolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Characterization of an adenosine deaminase-deficient human histiocytic lymphoma cell line (DHL-9) and selection of mutants deficient in adenosir kinase and deoxycytidine kinase.
Topics: Adenosine; Adenosine Deaminase; Adenosine Kinase; Cell Line; Deoxyadenosines; Deoxycytidine Kinase; Humans; Karyotyping; Lymphoma, Large B-Cell, Diffuse; Mutation; Nucleoside Deaminases; Phosphotransferases; Time Factors | 1983 |
Differential production of deoxyadenosine by human T and B lymphoblasts.
Topics: Adenosine; Adenosine Deaminase; Adenosine Deaminase Inhibitors; B-Lymphocytes; Cell Line; Coformycin; Deoxyadenosines; Humans; Interphase; Lymphocyte Activation; Lymphoma, Large B-Cell, Diffuse; Pentostatin; T-Lymphocytes | 1983 |
Chronic treatment with P2-purinergic receptor agonists induces phenotypic modulation of the HL-60 and U937 human myelogenous leukemia cell lines.
Topics: Actins; Adenosine; Adenosine Triphosphate; Calcium; Cell Differentiation; Cell Division; Cell Line; Genes, myc; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Lymphoma, Large B-Cell, Diffuse; N-Formylmethionine Leucyl-Phenylalanine; Phagocytes; Phenotype; Receptors, Purinergic; RNA, Messenger; Superoxides; Tetradecanoylphorbol Acetate; Uridine Triphosphate | 1991 |